Is the BFM Regimen Feasible for the Treatment of Adult XXXX ? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.

@entity1 @entity981 @entity137
UNASSIGNED: Multiple induction regimens have been developed for adult @entity1 with @entity981 ( @entity981 ). However, there have been no prospective randomized trials that directly compare these regimens. In this study, we wanted to evaluate the outcome of 50 @entity981 @entity1 treated with BFM (i.e. Berlin-Frankfurt-Munster, n = 20) and hyper-CVAD (n = 30) protocols between March 2006 and October 2012. The median age was 25 years in the BFM group and 30.5 years in the hyper-CVAD group with a male/female ratio of 15:5 and 17:13, respectively. Forty-five percent of the @entity1 in the BFM group and 30.3% in the hyper-CVAD group were <25 years old. The majority of cases were B cell in origin (80% in the BFM group and 70% in the hyper-CVAD group). Complete remission after induction therapy was achieved in 95 and 96% of the @entity1 , respectively. The median follow-up time was 37 months. The 5-year survival rate was higher in the BFM group than in the hyper-CVAD group (59 vs. 34%). There were also no complications which could cause a delay during the hyper-CVAD regimen. Both chemotherapies were well tolerated. None of the @entity1 died from drug-related @entity137 . Only mild liver enzyme elevations were seen as @entity137 in the BFM group; these did not cause any delay in therapy. The BFM regimen seems to be feasible for adult @entity1 with @entity981 in terms of tolerability and efficacy, especially in young adults.    2015 S. Karger AG, Basel.
